Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity
The introduction of biologic disease modifying anti-rheumatic drugs (bMDARDs) have revolutionised the treatment of psoriatic arthritis (PsA). This, combined with a ‘treat-to-target’ approach, means that achieving remission is increasingly possible. In patients with well-controlled PsA, there is litt...
| Main Authors: | , , |
|---|---|
| Formato: | Journal article |
| Publicado: |
Springer Verlag
2018
|